Objectives: To determine the significance of bladder neck involvement in predicting disease progression in superficial (stage Ta and T1) transitional cell carcinoma (TCC) of the urinary bladder. Patients and Methods: A series of 277 patients with newly diagnosed superficial TCCs of the bladder was reviewed, and disease progression (to T2 or worse) was considered. The significance of several risk factors including bladder neck involvement was assessed in univariate and multivariate analysis. Results: Progression occurred in 28 (10.1%) of 277 patients during a median follow-up period of 7.7 years. Nineteen died of bladder cancer. The following variables were found to be statistically significant at the univariate analysis (p < 0.05): irritative symptoms, urine cytology, tumor stage, involvement of the bladder neck, and tumor grade. Indeed, only involvement of the bladder neck, tumor stage, and grade retained their value as independent factors for progression at multivariate analysis. Patients were divided into three groups according to the number of independent risk factors they had. Groups having none, one, and two or three risk factors included 129, 99, and 49 patients with 5-year progression rates of 0.8, 4.6 and 27.5%, and 15-year rates of 4.0, 20.1 and 42.7%, respectively. Conclusion: Involvement of the bladder neck is a significant and independent risk factor for progression of superficial TCCs in addition to the histologic grade and stage. The combination of these three risk factors offers better prediction of progression in an individual patient.

Keywords:
Bladder cancer, Superficial carcinoma, Progression, Prognostic factors, Bladder neck
1.
Silverberg E, Boring CC, Squires TS: Cancer statistics, 1990. CA 1990;40:9–26.
2.
Soloway MS: Diagnosis and management of superficial bladder cancer. Semin Surg Oncol 1989;5:247–254.
3.
Abel PD: Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 1988;62:103–109.
4.
Witjes JA, Kiemeney LA, Oosterhof GO, Debruyne FM: Prognostic factors in superficial bladder cancer: A review. Eur Urol 1992;21:89–97.
5.
Lutzeyer W, Rubben H, Dahm H: Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 1982;127:250–252.
6.
Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR: Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083–1086.
7.
Narayana AS, Loening SA, Slymen DJ, Culp DA: Bladder cancer: Factors affecting survival. J Urol 1983;130:56–60.
8.
Huland H, Kloppel G, Otto U, Droese M: The value of histologic grading and staging, random biopsies, tumour and bladder mucosa blood group antigens, in predicting progression of superficial bladder cancer. Eur Urol 1984;10:28–31.
9.
Takashi M, Murase T, Mizuno S, Hamajima N, Ohno Y: Multivariate evaluation of prognostic determinants in bladder cancer. Urol Int 1987;42:368–374.
10.
Kalish LA, Garnick MB, Richie JP: Appropriate endpoints for superficial bladder cancer clinical trials. J Clin Oncol 1987;5:2004–2008.
11.
Stephenson WT, Holmes FF, Noble MJ, Gerald KB: Analysis of bladder carcinoma by subsite: Cystoscopic location may have prognostic value. Cancer 1990;66:1630–1635.
12.
Kurth KH, Denis L, Bouffioux Ch, Sylvester R, Debruyne FMJ, Pavone-Macaluso M, Oosterlinck W: Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31A:1840–1846.
13.
Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153:1444–1450.
14.
Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Feedman PC, Melamed MR, Whitmore WT: Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988;6:1450–1455.
15.
Vegt PDJ, Debruyne FMJ, van der Meijden APM: Bacillus Calmette-Guerin in superficial bladder cancer: Consensus and controversies. Eur Urol 1995;27:89–95.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.